BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother. 2010;11:919-928. [PMID: 20166841 DOI: 10.1517/14656561003637659] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells 2019;8:E376. [PMID: 31027278 DOI: 10.3390/cells8040376] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
2 Min JA, Yoon Y, Lee HJ, Choi J, Kwon M, Kim K, Lee CU, Kim DJ, Yun H. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea. J Med Virol 2013;85:575-82. [PMID: 23364858 DOI: 10.1002/jmv.23523] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
3 Habersetzer F, Leboeuf C, Doffoël M, Zeisel MB, Baumert TF. Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. Expert Opin Investig Drugs 2013;22:853-62. [PMID: 23634817 DOI: 10.1517/13543784.2013.794218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398-411. [PMID: 27575311 DOI: 10.1016/j.jhep.2016.08.009] [Cited by in Crossref: 157] [Cited by in F6Publishing: 150] [Article Influence: 26.2] [Reference Citation Analysis]
5 Mederacke I, Potthoff A, Meyer-olson D, Meier M, Raupach R, Manns MP, Wedemeyer H, Tillmann HL. HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. Journal of Clinical Virology 2012;53:110-5. [DOI: 10.1016/j.jcv.2011.11.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
6 Wiegand S, Jaroszewicz J, Potthoff A, Höner zu Siederdissen C, Maasoumy B, Deterding K, Manns M, Wedemeyer H, Cornberg M. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clinical Microbiology and Infection 2015;21:710.e1-9. [DOI: 10.1016/j.cmi.2015.03.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
7 Chen D. Fighting against viral hepatitis: Lessons from Taiwan. Hepatology 2011;54:381-92. [DOI: 10.1002/hep.24500] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
8 Lai CL, Yuen MF. Management of chronic hepatitis B in patients from special populations. Cold Spring Harb Perspect Med. 2015;5:pii a021527. [PMID: 26033083 DOI: 10.1101/cshperspect.a021527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
9 Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 2011;305:123-43. [PMID: 21168955 DOI: 10.1016/j.canlet.2010.11.014] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
10 Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013; 19(47): 8887-8894 [PMID: 24379612 DOI: 10.3748/wjg.v19.i47.8887] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
11 Serper M, Forde KA, Kaplan DE. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort. J Viral Hepat 2018;25:187-97. [PMID: 28845882 DOI: 10.1111/jvh.12784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
12 Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Reference Citation Analysis]
13 Shih W, Fang C, Chen P. Anti-Viral Treatment and Cancer Control. In: Chang MH, Jeang K, editors. Viruses and Human Cancer. Berlin: Springer Berlin Heidelberg; 2014. pp. 269-90. [DOI: 10.1007/978-3-642-38965-8_14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
14 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
15 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Yang Y, Zhou Y, Cheng W, Pan X, Xiao P, Shi Y, Gao J, Song X, Chen Y, Jiang Q. Prevalence and Determinants of Cryptosporidium Infection in an Underdeveloped Rural Region of Southwestern China. Am J Trop Med Hyg 2017;96:595-601. [PMID: 28093538 DOI: 10.4269/ajtmh.16-0732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
17 Wu ZY, Li H, Li JR, Lv XQ, Jiang JD, Peng ZG. Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I. Eur J Pharmacol 2019;853:111-20. [PMID: 30902657 DOI: 10.1016/j.ejphar.2019.03.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401-412. [PMID: 23199500 DOI: 10.1016/j.bpg.2012.09.009] [Cited by in Crossref: 148] [Cited by in F6Publishing: 142] [Article Influence: 16.4] [Reference Citation Analysis]
19 张莹, 颜学兵. 后DAA时代抗HCV治疗的现状及存在问题. 世界华人消化杂志 2017; 25(13): 1135-1142 [DOI: 10.11569/wcjd.v25.i13.1135] [Reference Citation Analysis]
20 Kondo Y, Ueno Y, Ninomiya M, Tamai K, Tanaka Y, Inoue J, Kakazu E, Kobayashi K, Kimura O, Miura M, Yamamoto T, Kobayashi T, Igarashi T, Shimosegawa T. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy. J Gastroenterol 2012;47:1323-35. [PMID: 22588246 DOI: 10.1007/s00535-012-0596-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
21 Yang D, Zuo C, Wang X, Meng X, Xue B, Liu N, Yu R, Qin Y, Gao Y, Wang Q. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci USA. 2014;111:E1264-E1273. [PMID: 24616513 DOI: 10.1073/pnas.1320071111] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
22 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
23 Wu Q, Li Z, Liu Q. An important role of SREBP-1 in HBV and HCV co-replication inhibition by PTEN. Virology 2018;520:94-102. [PMID: 29803738 DOI: 10.1016/j.virol.2018.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 805] [Article Influence: 77.0] [Reference Citation Analysis]
25 Alberti A, Caporaso N. HBV therapy: guidelines and open issues. Dig Liver Dis. 2011;43 Suppl 1:S57-S63. [PMID: 21195373 DOI: 10.1016/s1590-8658(10)60693-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]